Compass Therapeutics, Inc.
NASDAQ:CMPXBiotechnology
-$0.03 today
- Market cap
- $110.03M
- Beta
- 0.74
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$0.37
Volume 1.79M
Average 7.64M
CMPX Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Compass Therapeutics, Inc.NASDAQ: CMPX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows, but more slowly than its trailing trend
Q1 FY2026 net income of $18.32M (cash outflow) rose 10.1% year over year, behind the +23.5% change in trailing-twelve-month net income. Sequentially, it rose 16.6% from the prior quarter. Over 3 fiscal years it compounded at +19.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 7 analysts of -$81.73M (+22.9%) for the fiscal year ending Dec 2026, a slowdown from the +34.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$18.32M+16.6% QoQ
- Last fiscal yearDec 2025
- -$66.49M+34.7% YoY
- LTMMar 2026
- -$68.17M+23.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.1% | +4.0% | -6.1 pp |
| 1 year | +34.7% | +22.9% | -11.7 pp |
| 3-year CAGR | +19.2% | +21.9% | +2.7 pp |
| 5-year CAGR | -45.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (66.49M) USD
- Year-over-year change
- -34.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (66.49M) | -34.7% |
| FY2024 | 2024-12-31 | (49.38M) | -16.2% |
| FY2023 | 2023-12-31 | (42.49M) | -8.3% |
| FY2022 | 2022-12-31 | (39.23M) | +52.3% |
| FY2021 | 2021-12-31 | (82.18M) | — |
Net Income vs competitors
How CMPX compares with its peers on the latest reported figures
- CMPX's LTM Mar 2026 net income of $68.17M is the 8th largest of the 11 companies compared; the peer median is $73.89M.
- Its year-over-year change of +23.5% is the 5th highest of 10, against a peer median of +7.2%.
- Over three fiscal years its annual growth of +19.2% compares with a peer median of -9.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $218.8M | +7.2% | +24.8% | 344.6% | |
| LTM Mar 2026 | $180.4M | +252.1% | -9.4% | 324.8% | |
| LTM Mar 2026 | $160.9M | -8.8% | +9.2% | 182.3% | |
| LTM Dec 2025 | $138.44M | — | — | 119.4% | |
| LTM Mar 2026 | $81.36M | +148.9% | -73.6% | 822.4% | |
| LTM Mar 2026 | $76.12M | +14824.7% | -12.0% | — | |
| LTM Mar 2026 | $71.67M | +24.7% | -7.9% | 1605.2% | |
| LTM Mar 2026 | $68.17M | +23.5% | +19.2% | — | |
| LTM Mar 2026 | $44.17M | +6.7% | -28.2% | — | |
| LTM Mar 2026 | $26.09M | -85.3% | -21.0% | 37.5% | |
| LTM Mar 2026 | $14.98M | -9.6% | +9.3% | — | |
| Peer median (excluding CMPX) | $73.89M | +7.2% | -9.4% | 324.8% | |
Competitors are the stored peer set for CMPX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (82.18M) | (39.23M) | (42.49M) | (49.38M) | (66.49M) |
| Depreciation & Amortization | 1.62M | 1.9M | 1.89M | 1.75M | (1.4M) |
| Deferred Income Tax | 50.58M | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.03M | 5.33M | 6.12M | 8.56M | 8.37M |
| Change in Working Capital | 6.25M | (1.26M) | (2.91M) | (4.14M) | 9.18M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (194K) | 2.52M | 708K | (1.84M) | (664K) |
| Other Working Capital | 6.44M | (3.78M) | (3.62M) | (2.3M) | 9.84M |
| Other Non-Cash Items | 41K | (871K) | 5.97M | (1.65M) | 1.2M |
| Operating Cash Flow | (19.67M) | (34.13M) | (40.62M) | (44.86M) | (49.14M) |
| Capital Expenditures | (1.57M) | (212K) | (30K) | (44K) | (25K) |
| Acquisitions (Net) | 116K | 176K | 0 | 0 | 0 |
| Purchases of Investments | 0 | (200.12M) | (155.42M) | (88.16M) | (194.56M) |
| Sales of Investments | 0 | 48.96M | 182.41M | 134.97M | 101.28M |
| Other Investing Activities | (318K) | (150.99K) | 27K | 0 | 0 |
| Investing Cash Flow | (1.77M) | (151.2M) | 26.97M | 46.77M | (93.31M) |
| Debt Repayment | — | — | — | 0 | 0 |
| Common Stock Issued | 128.27M | 76.24M | 3.09M | 18.11M | 130.64M |
| Common Stock Repurchased | 0 | 0 | (159) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (281K) | (480K) | (159K) | (775K) | (1.03M) |
| Financing Cash Flow | 118.61M | 75.76M | 2.94M | 17.34M | 129.61M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 97.18M | (109.57M) | (10.72M) | 19.26M | (12.84M) |
| Free Cash Flow | (21.23M) | (34.34M) | (40.65M) | (44.9M) | (49.17M) |
Compass Therapeutics, Inc.
NASDAQ:CMPX
Intrinsic Alpha fair value
Locked
Current Price
$0.61
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.